Slingshot members are tracking this event:

Allergan and Adamas Announce New Expanded Indication for NAMZARIC (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details
-- Patients currently treated with donepezil hydrochloride 10 mg can now start therapy directly with once daily NAMZARIC --
-- NAMZARIC is the only Alzheimer's treatment that contains an NMDA receptor antagonist and an AChEI in a single capsule, a combination that demonstrated greater improvement in cognition and overall function compared to an AChEI alone. --
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Namzaric, Memantine Hydrochloride, Donepezil Hydrochloride, Alzheimer's Disease, Aricept, Namenda Xr, Achei, Acetylcholinesterase Inhibitor, Nmda Receptor Antagonist